Open AccessConsensus Statement on the Management of Waldenström Macroglobulinemia Patients During the COVID‐19 Pandemic
Author(s) -
Talaulikar Dipti,
Advani Ranjana H.,
Branagan Andrew R.,
Buske Christian,
Dimopoulos Meletios A.,
D'Sa Shirley,
Kersten Maria J.,
Leblond Veronique,
Minnema Monique C.,
Owen Roger G.,
Palomba Maria Lia,
Tedeschi Alessandra,
Trotman Judith,
Varettoni Marzia,
Vos Josephine M.,
Treon Steven P.,
Kastritis Efstathios,
Castillo Jorge J.
Publication year - 2020
Publication title -
hemasphere
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.677
H-Index - 11
ISSN - 2572-9241
DOI - 10.1097/hs9.0000000000000433
Subject(s) - medicine , covid-19 , waldenstrom macroglobulinemia , statement (logic) , pandemic , intensive care medicine , family medicine , hematology , pathology , political science , disease , infectious disease (medical specialty) , outbreak , lymphoma , law
In the light of the COVID‐19 pandemic, the International Workshop on Waldenström Macroglobulinemia (IWWM) Treatment Recommendations Panel felt the need to provide a consensus statement for the management of Waldenström Macroglobulinemia (WM) patients during this challenging time. We followed the current recommendations by the American Society of Hematology, which have been modified accordingly to fit the specific realities associated with the management of WM. In this Consensus Statement, the Panel addresses questions related to treatment initiation, preferred therapies, minimizing visit to clinics and infusions centers, supportive care and guidance for WM patients in clinical trials. Finally, we also provide information on timing and appropriateness of testing and management of COVID‐19 infected patients, as well as ways to get physicians and patients involved in registry studies that could help others.